Evidence map›Paper›PMID 36102142›Full record

ArticleVox sanguinis2022

Single-exon approach to non-invasive fetal RHD screening in early pregnancy: An update after 10 years' experience.

Mehmet Uzunel, Eleonor Tiblad, Anette Mörtberg, Agneta Wikman

Open access · hybridAbstract read
In one paragraph

Article in Vox sanguinis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Noninvasive fetal blood group antigen genotyping.Blood transfusion = Trasfusione del sangue · 2025
    Review
  4. Article
  5. Article
  6. FetalBiomedicines · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mehmet UzunelDivision of Therapeutic Immunology and Transfusion Medicine, Karolinska Institutet, Solna, Sweden.ORCID https://orcid.org/0000-0002-6803-6670
Eleonor TibladDepartment of Women's Health, Division of Obstetrics, Karolinska University Hospital, Stockholm, Sweden.
Anette MörtbergThe Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Agneta WikmanThe Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SEPublic Health Agency of Sweden · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAnti-D prophylaxis, administered to RhD-negative women, has significantly reduced the incidence of RhD immunization. Non-invasive fetal RHD screening has been used in Stockholm for more than 10 years to identify women who will benefit from prophylaxis. The method is based on a single-exon approach and is used in early pregnancy. The aim of this study was to update the performance of the method. MATERIALS AND

methodsThe single exon assay from Devyser AB is a multiplex kit detecting both exon 4 of the RHD gene and the housekeeping gene GAPDH. Cell-free DNA was extracted from 1 ml of plasma from EDTA blood taken during early pregnancy, weeks 10-12. The genetic RHD results were compared with serological typing of newborns for a determination of sensitivity and specificity.

resultsIn total, 4337 pregnancies were included in the study; 44 samples (1%) were inconclusive either due to maternal RHD gene variants (n = 34) or technical reasons (n = 10). Of the remaining 4293 pregnancies, a total number of nine discrepant results were found. False positive results (n = 7) were mainly (n = 4) due to RHD gene variants in the child. False-negative results were found in two cases, of which one was caused by a technical error. None of the false-negative cases was due to RHD gene variants. Overall, the sensitivity of the method was 99.93% and specificity 99.56%.

conclusionThe single-exon assay used in this study is correlated with high sensitivity and specificity.

Indexed as

Cell-Free Nucleic AcidsRh-Hr Blood-Group SystemChildExonsFemaleGenotypeHumansInfant, NewbornPregnancyPrenatal DiagnosisSensitivity and SpecificityCell-Free Nucleic AcidsRh-Hr Blood-Group Systemfetal RHDNIPT RHDsingle-exon

Identifiers

PMID36102142
PMCPMC9826394
OpenAlexW4295762087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.